For treatment of skeletal dysplasia, previous studies have shown that the soluble form of mutant FGFR2 and adeno‐associated virus‐mediated RNA interference partially prevent craniosynostosis in the Apert syndrome mouse model (Luo et al., 2018; Morita et al., 2014), while allogeneic mesenchymal stem cells have been used for engraftment in patients with osteogenesis imperfecta (Le Blanc et al., 2005). This evidence concerns the gene FGFR2 and skeletal dysplasia.